1-2 of 2 results for subject:Pain
Librarians' tools
- Search time
- 0.13 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pain
- We searched for
- subject_t:Pain OR subject_ses:92323
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of drugs for (a) epilepsy, (b) bipolar disorder and (c) neuropathic pain; and if he will make a statement.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of drugs for (a) epilepsy, (b) bipolar disorder and (c) neuropathic pain; and if he will make a statement.
Medicines supply problems can occur for a number of reasons due to manufacturing difficulties, regulatory problems and problems with the supply of raw materials, or from issues which are related to the distribution of the product. The manufacture of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards, so difficulties can arise for various reasons.
The Department understand that maintaining access to anti-epileptic drugs, drugs for bipolar disorder and those used in the management of neuropathic pain is vitally important to many people in this country. We are aware of some issues with medicines used in epilepsy, bipolar disorder and neuropathic pain over the past few months. During this time, we sought specialist advice to allow a clinical management plan to be developed. Expert clinicians provided input on the clinical management plan to ensure affected patients can be managed appropriately during the supply issue. We communicated any information about the supply issue and clinical management plan to the National Health Service including patient groups.
We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.
To ask the Secretary of State for Health and Social Care, how many Clinical Commissioning Groups have a pain threshold that patients must meet to be eligible for (a) knee and (b) hip replacement surgery.
To ask the Secretary of State for Health and Social Care, how many Clinical Commissioning Groups have a pain threshold that patients must meet to be eligible for (a) knee and (b) hip replacement surgery.
NHS England has advised that it does not hold this information.